Evidence map›Paper›PMID 40382442›Full record

ArticleCommunications medicine2025

Responses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes.

Avia D Wilkerson, Ivan Juric, Salendra Singh, Patricia A Rayman, Paul G Pavicic, Jennifer Powers, Prerana Bangalore Parthasarathy, Zahraa Al-Hilli, Jennifer S Ko, Timothy Chan and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Avia D WilkersonCleveland Clinic Foundation, Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-2185-9557
Ivan JuricCleveland Clinic Foundation, Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland, OH, USA.
Salendra SinghCleveland Clinic Foundation, Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-4903-9868
Patricia A RaymanCleveland Clinic Foundation, Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland, OH, USA.ORCID http://orcid.org/0000-0003-2206-370X
Paul G PavicicCleveland Clinic Foundation, Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-5772-3192
Jennifer PowersCleveland Clinic Foundation, Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland, OH, USA.
Prerana Bangalore ParthasarathyCleveland Clinic Foundation, Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland, OH, USA.
Zahraa Al-HilliCleveland Clinic Foundation, Department of General Surgery, Digestive Disease & Surgery Institute, Cleveland, OH, USA.
Jennifer S KoCleveland Clinic Foundation, Pathology and Laboratory Medicine Institute, Cleveland, OH, USA.
Timothy ChanCleveland Clinic Foundation, Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-9265-0283
Tyler AlbanCleveland Clinic Foundation, Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland, OH, USA. albant@ccf.org.ORCID http://orcid.org/0000-0002-3261-140X
Alberto J MonteroUniversity Hospitals/Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA. alberto.montero@uhhospitals.org.ORCID http://orcid.org/0000-0002-8221-8120
C Marcela Diaz-MonteroCleveland Clinic Foundation, Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland, OH, USA. cdiaz2@ccf.org.ORCID http://orcid.org/0000-0002-6941-4215

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGiven the scarcity of effective therapeutic targets, metastatic triple negative breast cancer (mTNBC) has shorter survival times compared to other advanced breast cancer subtypes. Although chemo-immunotherapy with immune checkpoint inhibitors (ICIs) in PD-L1

methodsWe employed single cell RNA sequencing (scRNAseq), single cell secretomics, and flow cytometry to identify transcriptomic and proteomic peripheral immune cell signatures associated with response and non-response to anti-PD-1/PD-L1 therapy and chemotherapy in mTNBC.

resultsTranscriptomic analysis reveal divergent transcriptional programming of CD33

conclusionOur findings highlight CD33

Identifiers

PMID40382442
PMCPMC12085700

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.